Zuuka Unveils Wearable Drug-Delivery Platform Targeting US $10bn Injectable Market
Zuuka, a New Zealand startup, is developing a wearable drug-delivery system aimed at enhancing adherence to chronic disease treatments. This innovation is positioned to capitalize on the growing US market for wearable insulin delivery devices, projected to expand significantly due to increased diabetes prevalence.
Theia Market Signal Identification - AI Assisted
Christchurch-based Zuuka is in the process of raising capital for the development of a wearable drug-delivery platform, targeting entry into the US market by 2029. The technology, developed by Dr. Jake Campbell from the University of Canterbury, aims to address adherence issues in chronic disease treatments such as diabetes and obesity.
The platform replaces traditional motor-driven systems with a low-power micro-actuator, allowing for a smaller device that lasts over a year without charging. This system could reduce medical waste by up to 99% compared to disposable pumps.
The company anticipates a substantial market opportunity, with the global insulin pump market projected to grow from $8.2 billion in 2026 to over $22 billion by 2034. Zuuka's approach to simplifying treatment management may significantly enhance long-term adherence, which is crucial for improving health outcomes.
Comments